Shenzhen Hepalink Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN

P/E

9.17

P/S

1.12

EPS

0.50

Div Yield, %

—

Shrs. gr., 5y

3.30%

Rev. gr., 5y

2.69%

Revenues

5.28b

-3.03%

Net income

647m

CFO

2.19b

+450.99%

Dividend

May 24, 20230.11215 HKD/sh

Profile

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

URL

https://www.hepalink.com/

IPO date

May 06, 2010

Employees

2,366

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	5,280,713 -3.03%	5,445,572 -23.94%	7,159,411 12.48%
Cost of revenue	4,191,268	4,420,062	5,742,148
Unusual Expense (Income)
NOPBT	1,089,445	1,025,510	1,417,262
NOPBT Margin	20.63%	18.83%	19.80%
Operating Taxes	101,311		115,164
Tax Rate	9.30%		8.13%
NOPAT	988,134	1,025,510	1,302,099
Net income	646,742 -182.57%	(783,258) -207.68%	727,426 202.10%
Dividends		(425,890)	(51,355)
Dividend yield		2.48%	0.27%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	1,838,944	3,624,575	4,056,474
Long-term debt	1,196,588	1,990,855	2,518,177
Deferred revenue	27,285	30,426	32,547
Other long-term liabilities	33,569	45,425	61,873
Net debt	(477,003)	835,627	1,971,764
Cash flow
Cash from operating activities	2,194,132	398,216
CAPEX		(444,878)
Cash from investing activities		1,221,569	249,840
Cash from financing activities		(1,202,972)	329,564
FCF	1,178,422	2,727,709	(705,248)
Balance
Cash	2,557,458	2,265,826	3,450,422
Long term investments	955,076	2,513,977	1,152,465
Excess cash	3,248,499	4,507,525	4,244,916
Stockholders' equity	5,553,432	3,085,724	6,721,513
Invested Capital	11,992,238	14,503,519	14,579,278
ROIC	7.46%	7.05%	9.82%
ROCE	7.04%	5.75%	7.40%
EV
Common stock shares outstanding	1,467,296	1,467,325	1,467,296
Price	10.69 -8.55%	11.69 -9.03%	12.85 -24.85%
Market cap	15,685,396 -8.56%	17,153,028 -9.03%	18,854,756 -24.85%
EV	15,261,842	18,063,884	20,923,244
EBITDA	1,420,496	1,399,106	1,724,922
EV/EBITDA	10.74	12.91	12.13
Interest	141,184	238,696	235,242
Interest/NOPBT	12.96%	23.28%	16.60%